Raloxifene-induced myeloma cell apoptosis: A study of nuclear factor-κB inhibition and gene expression signature

Molecular Pharmacology

Volumn 69, Issue 5, 2006, Pages 1615-1623

  Olivier, Sabine ^a   Close, Pierre ^a   Castermans, Emilie ^a   De Leval, Laurence ^a   Tabruyn, Sebastien ^a   Chariot, Alain ^a   Malaise, Michel ^a   Merville, Marie Paule ^a   Bours, Vincent ^a,b   Franchimont, Nathalie ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU B35   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE; CYCLIN G2; ESTROGEN RECEPTOR ALPHA; GADD34 PROTEIN; GENE PRODUCT; GLUCAGON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MYC PROTEIN; PROTEIN; PROTEIN P21; PROTEIN PAC 1; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SYNAPTOTAGMIN; TAMOXIFEN; TETRAZOLIUM; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BONE LESION; CELL ASSAY; CELL CYCLE; CELL CYCLE ARREST; CELL SURVIVAL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; MYELOMA CELL; NITROBLUE TETRAZOLIUM TEST; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; POLYMERASE CHAIN REACTION; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33645825623     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.020479     Document Type: Article

References (41)

1. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, and Roodman GD (2002) Multiple myeloma. Hematology Am Soc Hematol Educ Program 2002:214-240.
2. Bharti AC, Donato N, Singh S, and Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053-1062.
3. Bureau F, Vanderplasschen A, Jaspar F, Minner F, Pastoret PP, Merville MP, Bours V, and Lekeux P (2002) Constitutive nuclear factor-kappaB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins. Blood 99:3683-3691.
4. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, and Hampson G (2003) Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-β oestradiol and raloxifene. J Endocrinol 177:423-433.
5. Delhalle S, Deregowski V, Benoit V, Merville MP, and Bours V (2002) NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. Oncogene 21:3917-3924.
6. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, et al. (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617.
7. Fan F, Jin S, Amundson SA, Tong T, Fan W, Zhao H, Zhu X, Mazzacurati L, Li X, Petrik KL, et al. (2002) ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene 21:7488-7496.
8. Fassas AB, Rapoport AP, Bolanos-Meade J, Shanholtz C, Cottler-Fox M, and Tricot G (2001) Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation. Leuk Lymphoma 42:1323-1328.
9. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, and Siegel DS (1999) Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93:3044-3052.
10. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, and Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522-1533.
11. Galien R and Garcia T (1997) Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 25:2424-2429.
12. Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM, and Sola B (2005) 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. Clin Cancer Res 11:2345-2354.
13. Greten FR and Karin M (2004) The IKK/NF-kappaB activation pathway - a target for prevention and treatment of cancer. Cancer Lett 206:193-199.
14. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, and Karathanasis SK (2000) The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells. Endocrinology 141:3403-3411.
15. Hasegawa T, Xiao H, Hamajima F, and Isobe K (2000) Interaction between DNA-damage protein GADD34 and a new member of the Hsp40 family of heat shock proteins that is induced by a DNA-damaging reagent. Biochem J 352:795-800.
16. Heid CA, Stevens J, Livak KJ, and Williams PM (1996) Real time quantitative PCR. Genome Res 6:986-994.
17. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647.
18. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, et al. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534.
19. Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, and Wahl AF (1997) Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem 272:12650-12661.
20. Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC, and Fine HA (2004) Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res 64:9115-9123.
21. Kalaitzidis D and Gilmore TD (2005) Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab 16:46-52.
22. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, and Cummings SR (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751-1761.
23. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540-545.
24. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, et al. (2002a) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99:14374-14379.
25. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, and Anderson KC (2002b) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99:4079-4086.
26. Olivier S, Fillet M, Malaise M, Piette J, Bours V, Merville MP, and Franchimont N (2005) Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene. Biochem Pharmacol 69:891-901.
27. Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H, Yata K, Uno M, Yawata Y, and Ueki A (2000) Estrogen receptors in human myeloma cells. Cancer Res 60:1434-1441.
28. Panwalkar A, Verstovsek S, and Giles F (2004) Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 100:1578-1589.
29. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, and Lee YY (2000) Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60:3065-3071.
30. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, et al. (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65:6282-6293.
31. Richardson P (2003) Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 29 (Suppl 1):33-39.
32. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498.
33. Roodman GD (2004) Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32:290-292.
34. Roodman GD and Choi SJ (2004) MIP-1 alpha and myeloma bone disease. Cancer Treat Res 118:83-100.
35. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL, and Kuehl WM (2000) Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 97:228-233.
36. Tang TT, Dowbenko D, Jackson A, Toney L, Lewin DA, Dent AL, and Lasky LA (2002) The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem 277:14255-14265.
37. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, and Rahemtulla A (2003) Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 123:106-109.
38. Treon SP, Teoh G, Urashima M, Ogata A, Chauhan D, Webb IJ, and Anderson KC (1998) Anti-estrogens induce apoptosis of multiple myeloma cells. Blood 92:1749-1757.
39. Valentine JE, Kalkhoven E, White R, Hoare S, and Parker MG (2000) Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J Biol Chem 275:25322-25329.
40. Wang HY, Cheng Z, and Malbon CC (2003) Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 191:229-237.
41. Zhu JW, Field SJ, Gore L, Thompson M, Yang H, Fujiwara Y, Cardiff RD, Greenberg M, Orkin SH, and DeGregori J (2001) E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol Cell Biol 21:8547-8564.